MARC Record from harvard_bibliographic_metadata

LEADER: 03258cam a2200637 a 4500
001 011347025-8
005 20090417030839.0
008 070814s2007 njua b 001 0 eng
010 $a 2007934333
015 $aGBA770666$2bnb
016 7 $a013833579$2Uk
016 7 $a101463281$2DNLM
020 $a0691130086 (hbk. : alk. paper)
020 $a9780691130088 (hbk. : alk. paper)
035 0 $aocn154694691
040 $aNLM$cNLM$dUKM$dBTCTA$dYDXCP$dBAKER$dPIT$dVP@$dIAY$dTOZ
042 $apcc
043 $as-bl---
050 4 $aRA643.86.B6$bB54 2007
060 00 $a2008 A-284
060 10 $aWC 503.2$bB587w 2007
082 04 $a362.196979200981$222
100 1 $aBiehl, João Guilherme.
245 10 $aWill to live :$bAIDS therapies and the politics of survival /$cJoão Biehl ; photographs by Torben Eskerod.
260 $aPrinceton, N.J. ;$aWoodstock :$bPrinceton University Press,$cc2007.
300 $axii, 466 p. :$bill. ;$c25 cm.
490 1 $a[In-formation series]
500 $aSeries title from dust jacket.
504 $aIncludes bibliographical references (p. 425-449) and index.
505 0 $aIntroduction: A New World of Health -- 1. Pharmaceutical Governance -- 2. Circuits of Care -- 3. A Hidden Epidemic -- 4. Experimental Subjects -- 5. Patient-Citizenship -- 6. Will to Live -- Conclusion: Global Public Health.
520 1 $a"Will to Live tells how Brazil, against all odds, became the first developing country to universalize access to life saving AIDS therapies - a breakthrough made possible by an unexpected alliance of activists, government reformers, development agencies, and the pharmaceutical industry. But anthropologist Joao Biehl also tells why this policy, hailed as a model worldwide, has been so difficult to implement among poor Brazilians with HIV/AIDS, who are often stigmatized as noncompliant or untreatable, becoming invisible to the public. More broadly, Biehl examines the political economy of pharmaceutical that lies behind large scale treatment rollouts, revealing the possibilities and inequalities that come with a magic bullet approach to health care."--Jacket.
650 0 $aAIDS (Disease)$xPatients$xCare$zBrazil.
650 0 $aAIDS (Disease)$xPatients$zBrazil.
650 0 $aAIDS (Disease)$xPolitical aspects$zBrazil.
650 0 $aAIDS (Disease)$xTreatment$zBrazil.
650 0 $aAIDS activists$zBrazil.
650 0 $aMedical care$xPolitical aspects$zBrazil.
650 0 $aMedical care$zBrazil.
650 12 $aAcquired Immunodeficiency Syndrome$xdrug therapy
650 22 $aAntiviral Agents$xeconomics
650 22 $aAntiviral Agents$xtherapeutic use
650 22 $aBiotechnology$xeconomics
650 22 $aCost Control$xeconomics
650 22 $aPublic Policy
651 2 $aBrazil
650 0 $aAIDS (Disease)$xSocial aspects$zBrazil.
650 2 $aPublic Policy$zBrazil.
650 2 $aAntiviral Agents$xeconomics$zBrazil.
650 2 $aAcquired Immunodeficiency Syndrome$xdrug therapy$zBrazil
650 2 $aCost Control$xeconomics$zBrazil.
650 2 $aBiotechnology$xeconomics$zBrazil.
650 2 $aAntiviral Agents$xtherapeutic use$zBrazil.
700 1 $aEskerod, Torben,$d1960-
830 0 $aIn-formation series.
988 $a20110830
906 $0OCLC